HBIO Harvard Bioscience Inc
Price (delayed)
$2.79
Market cap
$121.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.25
Enterprise value
$158.02M
Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned
Highlights
Harvard Bioscience's debt has decreased by 16% YoY and by 2.3% from the previous quarter
HBIO's gross margin is up by 6% YoY
The company's net income has shrunk by 97% YoY and by 22% QoQ
The EPS has plunged by 92% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of HBIO
Market
Valuations
Earnings
Shares outstanding
43.61M
Market cap
$121.67M
Enterprise value
$158.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.8
Price to sales (P/S)
1.2
EV/EBIT
N/A
EV/EBITDA
178.55
EV/Sales
1.56
Revenue
$101.13M
EBIT
-$6.25M
EBITDA
$885,000
Free cash flow
$5.97M
Per share
Balance sheet
Liquidity
EPS
-$0.25
Free cash flow per share
$0.14
Book value per share
$1.55
Revenue per share
$2.33
TBVPS
$1.35
Total assets
$128.91M
Total liabilities
$61.67M
Debt
$40.39M
Equity
$67.25M
Working capital
$23.81M
Debt to equity
0.6
Current ratio
2.05
Quick ratio
0.73
Net debt/EBITDA
41.07
Margins
Efficiency
Dividend
EBITDA margin
0.9%
Gross margin
58.4%
Net margin
-10.6%
Operating margin
-4.9%
Return on assets
-7.9%
Return on equity
-15.1%
Return on invested capital
-8.3%
Return on capital employed
-5.9%
Return on sales
-6.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HBIO stock price
How has the Harvard Bioscience stock price performed over time
Intraday
-1.41%
1 week
2.2%
1 month
-5.42%
1 year
-33.73%
YTD
-47.85%
QTD
-2.11%
Financial performance
How have Harvard Bioscience's revenue and profit performed over time
Revenue
$101.13M
Gross profit
$59.04M
Operating income
-$5M
Net income
-$10.68M
Gross margin
58.4%
Net margin
-10.6%
HBIO's operating income has dropped by 199% year-on-year and by 134% since the previous quarter
Harvard Bioscience's operating margin has plunged by 145% from the previous quarter
Harvard Bioscience's net margin has plunged by 121% YoY and by 29% from the previous quarter
The company's net income has shrunk by 97% YoY and by 22% QoQ
Growth
What is Harvard Bioscience's growth rate over time
Valuation
What is Harvard Bioscience stock price valuation
P/E
N/A
P/B
1.8
P/S
1.2
EV/EBIT
N/A
EV/EBITDA
178.55
EV/Sales
1.56
The EPS has plunged by 92% YoY and by 25% from the previous quarter
HBIO's price to book (P/B) is 27% less than its last 4 quarters average of 2.5 and 24% less than its 5-year quarterly average of 2.4
The equity has declined by 11% year-on-year and by 2.3% since the previous quarter
The stock's price to sales (P/S) is 28% less than its last 4 quarters average of 1.7 and 24% less than its 5-year quarterly average of 1.6
Harvard Bioscience's revenue has decreased by 11% YoY and by 5% from the previous quarter
Efficiency
How efficient is Harvard Bioscience business performance
HBIO's return on invested capital has dropped by 168% year-on-year and by 36% since the previous quarter
The ROS has plunged by 148% YoY and by 35% from the previous quarter
The return on assets has dropped by 114% year-on-year and by 25% since the previous quarter
The return on equity has dropped by 104% year-on-year and by 26% since the previous quarter
Dividends
What is HBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HBIO.
Financial health
How did Harvard Bioscience financials performed over time
The total assets is 109% more than the total liabilities
HBIO's quick ratio is down by 22% YoY and by 3.9% QoQ
HBIO's current ratio is down by 10% year-on-year but it is up by 9% since the previous quarter
Harvard Bioscience's debt is 40% less than its equity
Harvard Bioscience's debt has decreased by 16% YoY and by 2.3% from the previous quarter
The equity has declined by 11% year-on-year and by 2.3% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.